Highest-materiality recent filing
Dyadic receives Nasdaq delisting notice for bid price and continued listing deficiencies
Nasdaq notified Dyadic on June 18, 2026 of failure to maintain minimum $1.00 bid price and meet continued listing standards.
Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus causing Hantavirus Pulmonary Syndrome.
Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share
Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
Dyadic receives Nasdaq deficiency notice for continued listing rule non-compliance
Received notice on March 27, 2026 for non-compliance with Nasdaq Listing Rule 5550(b) requiring $2.5M equity, $35M market value, or $500K net income.
Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M
Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.
Received Nasdaq deficiency notice on Dec 19, 2025; bid price below $1 for 30 consecutive business days.
Dyadic International Reports Q3 2025 Financial Results and Strategic Progress
Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.
Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes
Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.
Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering
Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).
Dyadic receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Nasdaq notified Dyadic that its common stock bid price closed below $1 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
Dyadic receives Nasdaq deficiency notice for MVLS below $35M threshold
Nasdaq staff notified Dyadic on June 23 that MVLS was below $35M for 30 consecutive business days.
Hazelton promoted to President, continues as COO; base salary raised 10% to $320,000; 25,000-share option grant with 4-year vesting.
Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants
Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.
Dyadic FY2024: revenue $3.5M (+21%), net loss $5.8M ($0.20/shr), cash $9.3M
Revenue $3.495M, up from $2.899M in 2023; driven by $1M Proliant license and $890k Inzymes success fees.
Dyadic receives $4.5M CEPI grant for C1 fungus-based vaccine development
CEPI awards $4.5M to non-profit FBS for proof-of-concept using Dyadic's C1 fungus to produce vaccine antigens.
Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development
Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.
Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M
Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.
Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M
Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.
Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.
Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.
Dyadic reports FY2023 net loss of $6.8M; appoints new Chairman and COO
Net loss $6.8M ($0.24/share) vs $9.7M loss in 2022; revenue $2.9M flat YoY.
Dyadic closes $6M convertible note financing with insider participation to fund commercialization
$6M aggregate principal, 8% senior secured convertible notes, due March 2027, conversion at $1.79/share.
Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023
Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).
Dyadic's collaboration with Janssen terminated; wind-down by Dec 31, 2023
Janssen Biotech provided written notice on Oct 2, 2023 to terminate the Research, License, and Collaboration Agreement with Dyadic.
Dyadic partners with MGH VIC and Voltron for vaccine antigens; part of $5.88M DoD award
Dyadic’s C1 platform to express vaccine antigens for influenza A and other infectious diseases.
Dyadic signs exclusive license deal with INZYMES for dairy enzymes; $0.6M upfront
Dyadic receives $0.6M upfront for development and licensing of Dapibus platform to INZYMES.
Dyadic Q2 net loss narrows to $2.15M; positive Phase 1 safety data for COVID booster DYAI-100
Net loss $2.15M (-$0.07/sh) vs -$3.29M (-$0.12/sh) YoY; revenue $837K up from $659K.
Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K
Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.
Revenue $2.93M (+21.9% YoY); net loss $9.7M ($0.34/share) vs $13.1M ($0.47) in 2021.
Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected
DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.
On May 29, 2025, the board of directors (the "Board") of Dyadic International, Inc. (the "Company") appointed Joseph Hazelton as President of the Company.
On April 28, 2025, Arindam Bose notified the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held on June 20, 2025.
Dr. Barry C. Buckland notified the Board of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held in June 2024.
the Board appointed Joseph Hazelton, its current Chief Business Officer, to the position of Chief Operating Officer, effective immediately.
appointed current member of the Board Patrick Lucy as its Chairman
Mr. Tarnok notified the Board of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held in June 2025.
Mr. Jones’ responsibilities for commercialization and business development will be transitioning to our new Chief Business Officer, Joe Hazelton.
On April 22, 2022, Dyadic International, Inc. (“Dyadic” or the “Company”) decided not to renew the consulting agreement the Company entered into with Novaro Ltd to engage Matthew Jones as its Managing Director of Business Development and Licensing.
Effective November 9, 2021, Dyadic International, Inc. (“Dyadic” or the “Company”) appointed Joseph Hazelton, age 46 as its Chief Business Officer.
Max materiality 0.90 · Median 0.60 · Most common event other_material